Results from the ASPIRE Trial: Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed Multiple Myeloma

December 7, 2014
Shaji Kumar, MD

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses the results of the phase III ASPIRE trial.

Clinical Pearls

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses the results of the phase III ASPIRE trial.

  • This trial looked at the combination of lenalidomide and dexamethasone with or without carfilzomib for patients with relapsed multiple myeloma.
  • Adding carfilzomib to lenalidomide and dexamethasone elicited an improvement in PFS.
  • The combination was well tolerated.

<<<

Go back to the ASH conference page